Kisspeptin

Kisspeptin (originally designated metastin when first identified) is a family of neuropeptides encoded by the KISS1 gene and processed by endogenous convertases into biologically active forms of varying lengths: kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10 — all sharing the same C-terminal decapeptide sequence (kisspeptin-10) that is responsible for the core biological activity. Kisspeptin-54 is the predominant circulating form in humans; kisspeptin-10 and shorter forms are produced locally in neural tissue through proteolytic processing and are the primary active forms at the G-protein-coupled receptor KISS1R (also known as GPR54), which is the cognate receptor for kisspeptin and the only receptor through which kisspeptin acts.

The discovery of kisspeptin's essential role in reproductive neuroendocrinology occurred in 2003–2004 and represented one of the most significant advances in reproductive endocrinology since the characterisation of GnRH in the 1970s. Two independent research groups — one studying human patients with idiopathic hypogonadotropic hypogonadism (IHH) and the other studying mice with targeted KISS1R gene deletions — simultaneously discovered that loss-of-function mutations or deletions of KISS1R caused complete failure of reproductive development: absence of puberty, absent gonadotropins (LH and FSH), absent sex steroids, and infertility — a phenotype of isolated hypogonadotropic hypogonadism that was not accompanied by any other hormonal or neurological defect. This observation established beyond reasonable doubt that kisspeptin-KISS1R signalling is an essential, non-redundant, and non-compensatable requirement for normal reproductive endocrine function in humans and mice.

The anatomy of kisspeptin's neuroendocrine actions centres on two populations of kisspeptin-producing neurons in the hypothalamus. The first population, located in the arcuate nucleus (ARC, also called the infundibular nucleus in humans), projects directly to GnRH neuron axonal terminals in the median eminence and drives pulsatile GnRH release. The ARC kisspeptin neurons are co-expressed with two other neuropeptides — neurokinin B (NKB) and dynorphin (Dyn) — forming the "KNDy" neurons that are now understood to be the hypothalamic pulse generator responsible for the rhythmic, episodic GnRH pulses (occurring approximately every 60–120 minutes in adult men and follicular-phase women) that drive pulsatile LH and FSH secretion from the pituitary. KNDy neurons interconnect with each other through NKB (excitatory, via NK3 receptor) and dynorphin (inhibitory, via kappa-opioid receptor) signalling to create the oscillatory circuit that generates the pulse. Kisspeptin released from the KNDy axonal terminals directly stimulates GnRH release via KISS1R on GnRH neuron axons.

The second kisspeptin neuron population, located in the anteroventral periventricular nucleus (AVPV), is sexually dimorphic and expressed at much higher density in females than males. AVPV kisspeptin neurons are responsible for the LH surge — the massive, coordinated GnRH/LH pulse that triggers ovulation at mid-cycle. Estradiol, rising in the late follicular phase, acts on AVPV kisspeptin neurons to stimulate rather than inhibit kisspeptin release (a positive feedback mechanism), which then drives the GnRH surge that produces the LH surge approximately 36 hours before ovulation. This estradiol-positive feedback action on AVPV kisspeptin neurons is the mechanistic key to the preovulatory LH surge and is absent in males (who only have kisspeptin's negative feedback regulation of the HPG axis).

The clinical applications of kisspeptin have been explored across several domains. In infertility medicine, kisspeptin-54 administered as a single subcutaneous injection has been studied by the Hammersmith Hospital (Imperial College London) group as an ovulation trigger in women undergoing in vitro fertilisation (IVF). The standard IVF ovulation trigger — hCG (human chorionic gonadotropin, which acts as an LH mimic at LH receptors) — carries a risk of ovarian hyperstimulation syndrome (OHSS), a potentially dangerous complication characterised by excessive ovarian response, fluid accumulation, and in severe cases, thrombosis and renal dysfunction. Women with polycystic ovary syndrome (PCOS) undergoing high-stimulation IVF protocols are at particularly high OHSS risk. Jayasena and colleagues demonstrated across multiple studies that kisspeptin-54 (9.6 nmol/kg subcutaneous) can reliably trigger oocyte maturation with dramatically lower OHSS risk than hCG, because kisspeptin acts via the endogenous GnRH-LH axis rather than directly mimicking LH, and the self-limiting nature of the endogenous surge constrains the ovarian response. This is now being explored in larger clinical trials as a potential paradigm shift in high-risk IVF ovulation triggering.

In hypogonadotropic hypogonadism (including functional hypothalamic amenorrhea in women and stress-induced suppression of GnRH pulsatility), kisspeptin has been studied as a means to re-activate the HPG axis by directly stimulating GnRH neurons — essentially bypassing whatever is suppressing the hypothalamic pulse generator upstream of GnRH neurons and directly forcing GnRH release. Unlike exogenous GnRH (which when given as a continuous infusion paradoxically suppresses the HPG axis through receptor downregulation, while pulsatile pump delivery is required for therapeutic effect), kisspeptin at appropriate doses activates endogenous GnRH neuron firing in a more physiological burst pattern. Research in this application is ongoing.

Male reproductive applications of kisspeptin include its potential to restore LH pulsatility in men with secondary hypogonadism, potentially offering an alternative to both testosterone replacement therapy (which suppresses endogenous HPG function) and exogenous LH/hCG therapy (which bypasses hypothalamic and pituitary function). Kisspeptin's ability to stimulate the entire HPG axis from the top of the cascade preserves the full LH-FSH-testosterone-sperm production axis, potentially maintaining fertility in a way that exogenous testosterone cannot.

The limbic and emotional-processing effects of kisspeptin beyond its strictly reproductive endocrine role have attracted growing research interest. Kisspeptin administrations in healthy men have been shown to alter brain activation patterns in the limbic system in response to sexual and olfactory stimuli, modulate mood states (increased positive affect in some studies), and affect reward-circuit responses. KISS1R expression in the limbic system — including amygdala, hippocampus, and nucleus accumbens — supports a role for kisspeptin in integrating reproductive readiness signals with emotional and motivational state, which makes evolutionary sense: reproductive behaviour requires not just hormonal permissiveness but emotional and motivational engagement.